Antonio Bertoletti
 | This article has no lead section. (January 2025) (Learn how and when to remove this template message) |
| Antonio Bertoletti | |
|---|---|
| Born | Cremona, Italy.[1] |
| 🎓 Alma mater | University of Parma[2] |
| 💼 Occupation | |
| Known for | Research on Hepatitis B Virus (HBV) and T cell therapies [1] |
| 🏅 Awards | EASL International Recognition Award (2023)[1], Singapore Translational Research (STaR) Investigator Award (2013[3], 2017 [4], 2024 [5]) |
Early Life and Education
Antonio Bertoletti was born in Cremona, Italy [1]. He earned his Doctor of Medicine degree from the University of Parma[7][8], where he began his research into viral hepatitis. During his specialization in Infectious Diseases, he conducted the first characterization of human HBV-specific CD8 T-cell responses in acute and chronic infection at The Scripps Research Institute in La Jolla, California [9][10].
Career
Dr. Bertoletti has held academic and research positions at several prestigious institutions, including:
- Research position at The Medical Research Council Unit in The Gambia [11].
- Senior Lecturer at the University College London Institute of Hepatology in London [12][1].
At UCL, Bertoletti, in collaboration with Andrew McMichael from the University of Oxford and Mala K. Maini, successfully used HLA-tetramers and measured HBV-specific T-cells in samples from HBV patients [13][14]. Their findings showed that HBV-specific CD8 frequencies in the blood and liver correlated with viral control. Their findings overturned the prevailing belief that antiviral T cells primarily caused hepatitis and highlighted their potential for immunotherapeutic boosting to suppress viral replication [13][14].
In 2006, he relocated to Singapore and initially led the Infection and Immunity Program at the Singapore Institute for Clinical Sciences (A*STAR) [15]. He joined Duke-NUS Medical School in 2013 as a full professor in the Emerging Infectious Diseases Programme [2]. During these years, his lab pioneered the use of genetically modified T cells targeting HBV envelope epitopes (HBsAg) as a therapy for hepatocellular carcinoma (HCC) [16][17]. His work included the first-in-man treatment demonstrating the safety and potential of this approach and highlighted the use of HBsAg fragments as tumor antigens for immunotherapy using the TCR-T cell therapy approach [18][19].
During the COVID-19 pandemic, his team directed focus towards the T-cell response against SARS-CoV-2 and published a series of seminal research articles [20][21][22][23] including a Nature article [24] which was ranked among the top 10 most downloaded in Nature and has already garnered over 2,100 citations [25].
Research Contributions
Dr. Bertoletti is renowned for his research on:
- The immunopathogenesis of HBV.
- Developing immunotherapies, including TCR-redirected T cells, to treat chronic HBV infections and related hepatocellular carcinoma.
- T cell immune responses in SARS-CoV-2 infections.
Antonio's research impact is evident from his recognition as a Highly Cited Researcher in the Cross-Field category for four consecutive years (2021–2024)[26][27].
Industry Contributions
In 2015, he founded Lion TCR Pte Ltd, a biotechnology company focused on developing immune-based treatments for virus-related cancers and chronic infections. The company has initiated clinical trials for HBV-related hepatocellular carcinoma in Singapore and China [28][29]
Awards and Recognition
- Singapore Translational Research (STaR) Investigator Award (2013[3], 2017 [4], 2024 [5])
- EASL International Recognition Award (2023) [1]
Publications
Prof. Bertoletti has authored over 100 peer-reviewed articles on viral hepatitis and immunology [30].
References
External Links
This article "Antonio Bertoletti" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Antonio Bertoletti. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "EASL International Recognition Award Recipient 2023: Prof. Antonio Bertoletti - Journal of Hepatology".
- ↑ 2.0 2.1 2.2 "Duke-NUS Medical School - Directory". DukeNUS.
- ↑ 3.0 3.1 "NMRC | Awarded Projects". www.nmrc.gov.sg.
- ↑ 4.0 4.1 https://www.nmrc.gov.sg/docs/default-source/grants-library/awardedproj/17-nov-awarded-projects_td.pdf?sfvrsn=36b6468c_0
- ↑ 5.0 5.1 https://www.nmrc.gov.sg/docs/default-source/grants-library/awardedproj/24-jan-awarded-projects_tda5681b2407e84accb12489761b1b205d.pdf?sfvrsn=2b8051b5_0
- ↑ https://www.duke-nus.edu.sg/eid/faculty/tenure-track-faculty
- ↑ "Antonio Bertoletti-新加坡杜克大学". www.sciconf.cn.
- ↑ "Antonio Bertoletti". Asia Research News. September 27, 2021.
- ↑ Bertoletti, A; Ferrari, C; Fiaccadori, F; Penna, A; Margolskee, R; Schlicht, H J; Fowler, P; Guilhot, S; Chisari, F V (December 2, 1991). "HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen". Proceedings of the National Academy of Sciences. 88 (23): 10445–10449. Bibcode:1991PNAS...8810445B. doi:10.1073/pnas.88.23.10445. PMC 52945. PMID 1660137.
- ↑ Bertoletti, Antonio; Sette, Alessandro; Chisari, Francis V.; Penna, Amalia; Levrero, Massimo; Carli, Marco De; Fiaccadori, Franco; Ferrari, Carlo (June 2, 1994). "Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells". Nature. 369 (6479): 407–410. Bibcode:1994Natur.369..407B. doi:10.1038/369407a0. PMID 8196768 – via www.nature.com.
- ↑ https://www.duke-nus.edu.sg/medicus/2024-issue4/antonio-bertoletti
- ↑ "Principal Investigator". December 29, 2023.
- ↑ 13.0 13.1 "Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection - Gastroenterology".
- ↑ 14.0 14.1 Maini, Mala K.; Boni, Carolina; Lee, Chun Kyon; Larrubia, Juan R.; Reignat, Stephanie; Ogg, Graham S.; King, Abigail S.; Herberg, Jethro; Gilson, Richard; Alisa, Akeem; Williams, Roger; Vergani, Diego; Naoumov, Nikolai V.; Ferrari, Carlo; Bertoletti, Antonio (April 10, 2000). "The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection". Journal of Experimental Medicine. 191 (8): 1269–1280. doi:10.1084/jem.191.8.1269. PMC 2193131. PMID 10770795 – via Silverchair.
- ↑ "Antonio Bertoletti". A*STAR Research.
- ↑ https://www.sigmaaldrich.com/SG/en/collections/webinars/personalized-t-cell-therapy?srsltid=AfmBOoqyULv8XTXgPDpfegwIfXJ0748ntpA7XPoklZuQ41W2s6GfK3EA
- ↑ "Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines - Journal of Hepatology".
- ↑ "PRESS RELEASE Report". www.nas.gov.sg.
- ↑ "Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient - Journal of Hepatology".
- ↑ Tan, Anthony T.; Lim, Joey M. E.; Bert, Nina Le; Kunasegaran, Kamini; Chia, Adeline; Qui, Martin D. C.; Tan, Nicole; Chia, Wan Ni; Alwis, Ruklanthi de; Ying, Ding; Sim, Jean X. Y.; Ooi, Eng Eong; Wang, Lin-Fa; Chen, Mark I.-Cheng; Young, Barnaby E.; Hsu, Li Yang; Low, Jenny G. H.; Lye, David C.; Bertoletti, Antonio (September 1, 2021). "Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals". The Journal of Clinical Investigation. 131 (17). doi:10.1172/JCI152379. PMC 8409582 Check
|pmc=value (help). PMID 34623327 Check|pmid=value (help). - ↑ Lim, Joey Ming Er; Tan, Anthony Tanoto; Le Bert, Nina; Hang, Shou Kit; Low, Jenny Guek Hong; Bertoletti, Antonio (October 3, 2022). "SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity". The Journal of Experimental Medicine. 219 (10): e20220780. doi:10.1084/jem.20220780. PMC 9386509 Check
|pmc=value (help). PMID 35972472 Check|pmid=value (help). - ↑ Samandari, Taraz; Ongalo, Joshua B.; McCarthy, Kimberly D.; Biegon, Richard K.; Madiega, Philister A.; Mithika, Anne; Orinda, Joseph; Mboya, Grace M.; Mwaura, Patrick; Anzala, Omu; Onyango, Clayton; Oluoch, Fredrick O.; Osoro, Eric; Dutertre, Charles-Antoine; Tan, Nicole; Hang, Shou Kit; Hariharaputran, Smrithi; Lye, David C.; Herman-Roloff, Amy; Bert, Nina Le; Bertoletti, Antonio (July 3, 2023). "Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults". The Journal of Clinical Investigation. 133 (13). doi:10.1172/JCI170011. PMC 10313370 Check
|pmc=value (help). PMID 37219944 Check|pmid=value (help). - ↑ Swadling, Leo; et al. (January 2, 2022). "Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2". Nature. 601 (7891): 110–117. Bibcode:2022Natur.601..110S. doi:10.1038/s41586-021-04186-8. PMC 8732273 Check
|pmc=value (help). PMID 34758478 Check|pmid=value (help). - ↑ Le Bert, Nina; Tan, Anthony T.; Kunasegaran, Kamini; Tham, Christine Y. L.; Hafezi, Morteza; Chia, Adeline; Chng, Melissa Hui Yen; Lin, Meiyin; Tan, Nicole; Linster, Martin; Chia, Wan Ni; Chen, Mark I.-Cheng; Wang, Lin-Fa; Ooi, Eng Eong; Kalimuddin, Shirin; Tambyah, Paul Anantharajah; Low, Jenny Guek-Hong; Tan, Yee-Joo; Bertoletti, Antonio (August 2, 2020). "SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls". Nature. 584 (7821): 457–462. doi:10.1038/s41586-020-2550-z. PMID 32668444 Check
|pmid=value (help). - ↑ "Altmetric – SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls". nature.altmetric.com.
- ↑ "Web of Science". www.webofscience.com.
- ↑ "NUS researchers ranked among the world's most impactful scholars". NUS researchers ranked among the world’s most impactful scholars.
- ↑ "Antonio Bertoletti". Croucher Foundation.
- ↑ "LionTCR | Company". www.liontcr.com.
- ↑ "Antonio Bertoletti". scholar.google.com.sg.
